Veru Inc. reported positive data from Phase 2b QUALITY study, showing enobosarm with semaglutide preserved muscle, increased fat loss, and reduced gastrointestinal side effects. Results from QUALITY Maintenance Extension study also showed benefits after semaglutide discontinuation. A novel modified release oral enobosarm formulation has been selected, awaiting FDA feedback for regulatory pathway clarification. The Company will host a conference call and webcast at 8:00 a.m. ET.

In the Phase 2b QUALITY study, enobosarm 3mg with semaglutide preserved total lean mass, leading to greater fat loss compared to placebo. The Maintenance Extension study demonstrated enobosarm’s ability to prevent body weight and fat regain after semaglutide discontinuation. The new oral formulation of enobosarm has shown promising results in clinical studies.

Veru Inc. released their financial results for the third quarter of fiscal 2025, showing a decrease in operating expenses compared to the previous year. Cash, cash equivalents, and restricted cash as of June 30, 2025, were $15.0 million. The Company’s drug development program focuses on innovative medicines for cardiometabolic and inflammatory diseases, with enobosarm and sabizabulin being key candidates.

The Phase 2b QUALITY and Maintenance Extension studies have demonstrated the efficacy of enobosarm in preserving lean mass, reducing fat, and improving physical function. The Company awaits FDA feedback on the regulatory pathway for enobosarm. Financially, the Company has seen a decrease in operating expenses and an increase in research and development expenses year-to-date for fiscal 2025.

Read more at GlobeNewswire: Veru Reports Fiscal 2025 Third Quarter Financial Results